Vincent R.
- Country
- Belgium
- Department
- Oncology
Research Overview
- Phase II Randomized Trial of Neoadjuvant Chemotherapy and Stereotactic Body Radiotherapy with Durvalumab and Oleclumab in Luminal B Breast Cancer
- RADAR: A randomised phase III trial with a PET response adapted design comparing ABVD +/- ISRT with A2VD +/- ISRT in patients with previously untreated stage IA/IIA Hodgkin lymphoma
Data & Insights
Has run more than one trial at 3 of 23 partner sites.
Specializations
Breast Cancer Research
The investigator specializes in innovative approaches to treating luminal B breast cancer, combining multiple therapeutic modalities. Their research explores the integration of neo-adjuvant chemotherapy with stereotactic body radiotherapy to primary tumors.
- Advanced Treatment Combinations
- Primary Tumor Response Assessment
- Nodal Metastases Management
Their work focuses on evaluating tumor response patterns in both primary sites and nodal regions.
Lymphoma Treatment
The investigator conducts research in the treatment of early-stage Hodgkin lymphoma, with particular emphasis on PET-response adapted therapy. Their work explores optimized treatment protocols for stage IA/IIA disease.
- Treatment Protocol Optimization
- Progression-Free Survival Assessment
- Response-Adapted Therapeutic Approaches
The research encompasses comparative analyses of different therapeutic regimens to enhance treatment outcomes.
Imaging and Response Assessment
The investigator utilizes advanced imaging techniques for treatment response evaluation, particularly incorporating PET scanning in treatment planning and monitoring.
- Response Monitoring Protocols
- Imaging-Based Treatment Adaptation
- Therapeutic Response Assessment
Their approach integrates diagnostic imaging for precise treatment planning and outcome evaluation.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.